Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers

Gynecologic Oncology

Volumn 109, Issue 3, 2008, Pages 346-352

  Morris, Robert ^a   Alvarez, Ronald D ^b   Andrews, Stephen ^c   Malone, John ^d   Bryant, Christopher ^d   Heilbrun, Lance K ^a   Smith, Daryn ^a   Schimp, Veronica ^a   Munkarah, Adnan ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF TOLEDO MEDICAL CENTER   (United States)

^d ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Platinum sensitive ovarian cancer; Relapsed ovarian cancer; Topotecan; Weekly topotecan

Indexed keywords

PLATINUM; TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVARY CANCER; PAIN; PATIENT COMPLIANCE; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROSPECTIVE STUDIES; SURVIVAL RATE; TOPOTECAN;

EID: 44549084683     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.02.028     Document Type: Article

References (27)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Dunton C.J. Management of treatment-related toxicity in advanced ovarian cancer. Oncologist 7 suppl 5 (2002) 11-19
3. Armstrong D.K. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 7 suppl 5 (2002) 20-28
4. Parmar M.K., Ledermann J.A., Colombo N., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (2003) 2099-2106
5. Pfisterer J., Plante M., Vergote I., et al. Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG (abstr 5005). Proc Am Assoc Cancer Res 23 (2004) 449s
6. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., and Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19 (2001) 3312-3322
7. ten Bokkel Huinink W., Lane S.R., and Ross G.A. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 15 (2004) 100-103
8. Rowinsky E.K. Weekly topotecan: an alternative to topotecan's standard daily × 5 schedule?. Oncologist 7 (2002) 324-330
9. Morris R., and Munkarah A. Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer. Oncologist 7 suppl 5 (2002) 29-35
10. Rodriguez M., and Rose P.G. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecol Oncol 83 (2001) 257-262
11. Safra T., Menczer J., Bernstein R., et al. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gynecol Oncol 105 (2007) 205-210
12. Bence A.K., Mattingly C.A., and Desimone P.A. Evaluation of topotecan cytotoxicity and topoisomerase I levels in non-small cell lung cancer cells (poster). Proc Am Assoc Cancer Res 43 (2002) 247
13. Bhoola S.M., Coleman R.L., Herzog T., et al. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol Oncol 95 (2004) 564-569
14. Homesley H.D., Hall D.J., Martin D.A., et al. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol 83 (2001) 394-399
15. Levy T., Inbar M., Menczer J., Grisaru D., Glezerman M., and Safra T. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol Oncol 95 (2004) 686-690
16. O'Malley D.M., Azodi M., Makkenchery A., et al. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 98 (2005) 242-248
17. Tan B.R., Picus J., Fracasso P.M., and Clark R. Weekly bolus topotecan (T): update on a phase I dose escalation trial (abstr 2147). Proc Am Soc Clin Oncol 21 (2002) 84b
18. McGuire W.P., Blessing J.A., Bookman M.A., Lentz S.S., and Dunton C.J. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 18 (2000) 1062-1067
19. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10 (1989) 1-10
20. Casella G. Refining binomial confidence intervals. Can J Stat 14 (1987) 113-129
21. Mehta C., and Patel N. StatXact-6: statistical software for exact nonparametric inference. User manual (2003), Cytel Software Corp, Cambridge, MA
22. Lee E.T., and Wang J.W. Statistical methods for survival data analysis. 3rd ed. (2003), Wiley & Sons, Hoboken, NJ
23. Bookman M.A., Malmstrom H., Bolis G., et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 16 (1998) 3345-3352
24. Creemers G.J., Bolis G., Gore M., et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 14 (1996) 3056-3061
25. Hoskins P., Eisenhauer E., Beare S., et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 16 (1998) 2233-2237
26. Kudelka A.P., Tresukosol D., Edwards C.L., et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14 (1996) 1552-1557
27. ten Bokkel Huinink W., Gore M., Carmichael J., et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15 (1997) 2183-2193